The GNPDA2 Knockout SK-HEP-1 Polyclonal Cells comprise a heterogeneous population of human SK-HEP-1 liver adenocarcinoma cells engineered via CRISPR/Cas9-mediated disruption of the GNPDA2 gene. This polyclonal knockout product provides a loss-of-function model for studying the hexosamine biosynthesis pathway in the context of hepatocellular carcinoma. As a polyclonal cell population, it retains genetic diversity beyond the targeted locus, recapitulating a more physiological cellular context compared to monoclonal derivatives. The knockout is achieved through general CRISPR/Cas9 gene disruption, rendering the cells deficient in functional GNPDA2 protein without specifying the exact editing pattern.
The SK-HEP-1 cell line, originally derived from a human liver adenocarcinoma, is a widely used hepatocellular carcinoma model. Its epithelial morphology and robust growth characteristics make it amenable to genetic manipulation and well-suited for investigating liver cancer biology, metabolic reprogramming, and therapeutic strategies.
GNPDA2 encodes glucosamine-6-phosphate deaminase 2, which catalyzes the deamination of glucosamine-6-phosphate to fructose-6-phosphate and ammonia, a pivotal step in the hexosamine biosynthesis pathway. This reaction regulates the flux of glucose-derived metabolites into UDP-GlcNAc production, thereby influencing O-GlcNAcylation and cellular metabolic signaling. GNPDA2 functions downstream of the rate-limiting enzyme GFPT1 and interacts with O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA). Its expression is activated by glucose and insulin through the transcription factor ChREBP, while AMPK exerts inhibitory control. Together with pathway components GNPNAT1, PGM3, and UAP1, GNPDA2 balances hexosamine flux with glycolytic intermediate levels.
In hepatocellular carcinoma, altered hexosamine pathway activity and dysregulated O-GlcNAcylation contribute to metabolic reprogramming, proliferation, and survival. Disruption of GNPDA2 in SK-HEP-1 cells provides a relevant model to investigate how abrogating this enzyme impacts UDP-GlcNAc synthesis and O-GlcNAc-mediated signaling in liver cancer. Given GNPDA2??s genetic associations with obesity and type 2 diabetes, this knockout system also enables study of nutrient-sensing pathways that link metabolic disease to hepatocellular carcinoma progression.
Researchers can employ this knockout population in assays such as Western blotting for O-GlcNAcylation, RT-qPCR for pathway gene expression, UDP-GlcNAc metabolite profiling, Seahorse metabolic flux analysis, MTT proliferation assays, Annexin V apoptosis assessment, wound-healing migration assays, and colony formation studies. These tools facilitate detailed mechanistic and functional investigations of GNPDA2 in hepatocellular carcinoma and metabolic disease contexts. For further information, please contact Ascent Research.
